Misplaced Pages

Demoxytocin

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Chemical compound Pharmaceutical compound
Demoxytocin
Clinical data
Other namesODA-914;
1-mercaptopropionate-
oxytoxin
Routes of
administration		Buccal
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
IUPAC name
  • 2--6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl]carbonyl}pyrrolidin-2-yl)formamido]-N-(carbamoylmethyl)-4-methylpentanamide
CAS Number
PubChem CID
ChemSpider
UNII
ChEBI
CompTox Dashboard (EPA)
ECHA InfoCard100.003.668 Edit this at Wikidata
Chemical and physical data
FormulaC43H65N11O12S2
Molar mass992.18 g·mol
3D model (JSmol)
SMILES
  • CC(C)1C(=O)N(C(=O)N(C(=O)N(CSSCCC(=O)N(C(=O)N1)Cc2ccc(cc2)O)C(=O)N3CCC3C(=O)N(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N
InChI
  • InChI=1S/C43H65N11O12S2/c1-5-23(4)36-42(65)49-26(12-13-32(44)56)38(61)50-29(19-33(45)57)39(62)52-30(21-68-67-16-14-35(59)48-28(40(63)53-36)18-24-8-10-25(55)11-9-24)43(66)54-15-6-7-31(54)41(64)51-27(17-22(2)3)37(60)47-20-34(46)58/h8-11,22-23,26-31,36,55H,5-7,12-21H2,1-4H3,(H2,44,56)(H2,45,57)(H2,46,58)(H,47,60)(H,48,59)(H,49,65)(H,50,61)(H,51,64)(H,52,62)(H,53,63)/t23-,26-,27-,28-,29-,30-,31-,36-/m0/s1
  • Key:GTYWGUNQAMYZPF-QPLNMOKZSA-N

Demoxytocin (INN) (brand names Sandopart, Odeax, Sandopral), also known as desaminooxytocin or deaminooxytocin, as well as 1-(3-mercaptopropanoic acid)oxytocin (OT), is an oxytocic peptide drug that is used to induce labor, promote lactation, and to prevent and treat puerperal (postpartum) mastitis (breast inflammation). Demoxytocin is a synthetic analogue of oxytocin and has similar activities, but is more potent and has a longer half-life in comparison. Unlike oxytocin, which is given via intravenous injection, demoxytocin is administered as a buccal tablet formulation.

The drug was first synthesized in 1960 and was introduced into clinical practice in 1971 by Sandoz. It is marketed in several European countries, including Italy, Czech Republic, and Poland. It has the amino acid sequence Mpa-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2 (Mpa = β-mercaptopropionic acid), and is an analogue of oxytocin wherein the leading cysteine is replaced with β-mercaptopropionic acid.

Uses and Impact

Labour was induced or stimulated after random allocation of the mothers to one of three oxytocics (prostaglandin E2 orally, oxytocin intravenously, or demoxytocin buccally).Using as models, the neurohypophyseal nonapeptide hormone oxytocin and its analogue deaminooxytocin, several directed routes to formation of sulfur-sulfur bridges have been developed and evaluated. PGE2 tablets (Prostin) were given to 109 parturients and demoxytocin resoriblets (Sandopart) to 84. Use of oral oxytocics for stimulation of labor in cases of premature rupture of the membranes at term. A randomized comparative study of prostaglandin E2 tablets and demoxytocin resoriblets. The efficacy of oral PGE2 tablets and buccal demoxytocin (resoriblets) for the induction of labor in cases of premature rupture of the membranes (PROM) after the 37th week of gestation has been evaluated in a prospective, randomized investigation of 193 women.

Pharmacology

Pharmacodynamics

Demoxytocin is a peptide analogue of oxytocin and acts as an oxytocin receptor agonist.

See also

References

  1. ^ Bladon C (3 April 2002). "Modifications of Endogenous Peptides and Proteins". Pharmaceutical Chemistry: Therapeutic Aspects of Biomacromolecules. John Wiley & Sons. pp. 61–. ISBN 978-0-471-49637-3.
  2. ^ Morton IK, Hall JM (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 93–. ISBN 978-94-011-4439-1.
  3. Sternadel Z, Gerkowicz J (May 1979). "". Ginekologia Polska (in Polish). 50 (5): 413–416. PMID 468056.
  4. van Boxtel CJ (6 August 2008). "Hormones and Hormone Antagonists". In van Boxtel CJ, Santoso B, Edwards IR (eds.). Drug Benefits and Risks: International Textbook of Clinical Pharmacology (2nd ed.). IOS Press. pp. 389–. ISBN 978-1-60750-345-3.
  5. Thiery M (22 October 2013). "Stimulation of uterine activity". In Eskes TK, Finster M (eds.). Drug Therapy During Pregnancy. Elsevier. pp. 185–. ISBN 978-1-4831-6298-0.
  6. ^ Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 349–. ISBN 978-1-4757-2085-3.
  7. Gross E, Meienhofer J (10 May 2014). "The Peptide Bond". In Gross E, Meienhofer J (eds.). Major Methods of Peptide Bond Formation: The Peptides Analysis, Synthesis, Biology. Elsevier. pp. 53–. ISBN 978-1-4832-1796-3.
  8. Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. pp. 301–. ISBN 978-3-88763-075-1.
Uterotonics/labor inducers/oxytocics (G02A)
Cervical ripening
Ergot alkaloids
Prostaglandins and
analogues
Contraction induction
Obstetric drugs
Induction and augmentation of labour
Prevention and treatment of hemorrhage
Induction of abortion
Oxytocin and vasopressin receptor modulators
Oxytocin
Vasopressin
V1A
V1B
V2
Unsorted
Others
Categories: